SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hauke RJ, Armitage JO. A new approach to non Hodgkin's lymphoma. Int Med 2000; 39: 197.
  • 2
    Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 7588.
  • 3
    Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 4049.
  • 4
    Johnston LJ, Stockert-Goldstain KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 55562.
  • 5
    Hiddemann W, Griesinger F, Unterhalt M. Interferon alfa for the treatment of follicular lymphomas. Cancer J Sci Am 1998; 4: S138.
  • 6
    Dillman RO. Monoclonal antibody therapy for lymphoma. Cancer Pract 2001; 9: 7180.
  • 7
    Vellken H, Osterroth F. Vaccination strategies in the treatment of lymphomas. Oncology 2002; 62: 187200.
  • 8
    Bendandi M. Role of anti-idiotype vaccines in the treatment of human follicular lymphoma. Expert Rev Anticancer Ther 2001; 1: 8996.
  • 9
    Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma. Nature 1993; 362: 755.
  • 10
    Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 2538.
  • 11
    Armstrong AC, Dermime S, Allison CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor protective immunity and identification of a idiotype-specific T cell epitope. J Immunol 2002; 168: 398391.
  • 12
    Timmerman JM, Clemens B, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 2001; 97: 13707.
  • 13
    Benvenuti F, Burrone OR, Efremov DG. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Ther 2000; 7: 60511.
  • 14
    King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4: 12816.
  • 15
    Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 2002; 87: 9891001.
  • 16
    Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996; 26: 26719.
  • 17
    Schultze JL. Why do B cell lymphoma fail to elicit clinically sufficient immune responses. Leuk Lymphoma 1999; 32: 223.
  • 18
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162: 500310.
  • 19
    Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 385865.
  • 20
    Tham EL, Mescher MF. The post stimulation program of CD4 vs. CD8 T cells (death vs. activation-induced non responsiveness). J Immunol 2002; 169: 18228.
  • 21
    Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100: 275765.
  • 22
    van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 217.
  • 23
    Briones J, Timmerman J, Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002; 62: 31959.
  • 24
    Lode HN, Xiang R, Pertl U, Forster E, Schoenberger SP, Gillies SD, Reisfeld RA. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest 2000; 105: 162330.
  • 25
    Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397403.
  • 26
    Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 121724.
  • 27
    Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997; 89: 1595601.
  • 28
    Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001; 61: 4497505.
  • 29
    Pasquini S, Peralta S, Missiaglia E, Carta L, Lemoine NR. Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther 2002; 9: 50310.
  • 30
    Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979; 122: 54954.
  • 31
    Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 18429.
  • 32
    Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 2000; 7: 1467.
  • 33
    Kaplan HS. Role of immunologic disturbance in human oncogenesis: some facts and fancies. Br J Cancer 1971; 25: 62034.
  • 34
    Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 30919.
  • 35
    Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 13203.
  • 36
    Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 4803.
  • 37
    Kikuchi T, Miyazawa N, Moore MS, Crystal RG. Tumor regression induced by intratumoral administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000; 60: 63915.
  • 38
    Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, Sallan SE, Rolink AG, Mantovani A, Nadler LM, Cardoso AA. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 2001; 98: 53340.
  • 39
    McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69: 6816.
  • 40
    Cheever MA, Chen W. Therapy with cultured T cells: principles revisited. Immunol Rev 1997; 157.
  • 41
    Rosenberg SA, Lotz MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 1986; 4: 681709.
  • 42
    Shrikant P, Mescher MF. Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J Immunol 2002; 169: 17539.
  • 43
    Takahashi S, Yotnda P, Rousseau RF, Mei Z, Smith S, Rill D, Younes A, Brenner MK. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001; 8: 37887.
  • 44
    Aghi M, Chiocca EA. Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 2003; 21: 27892
  • 45
    Buning H, Nicklin SA, Perabo L, Hallek M, Baker AH. AAV-based gene transfer. Curr Opin Mol Ther 2003; 5: 36775.